Research output per year
Research output per year
Personal profile
Biography
Jonathan Knikman, PhD, PharmD, Clinical Pharmacologist, works as an assistant professor at the Julius Center for Health Sciences & Primary Care, Department of Public Global Health & Bioethics. Trained as a pharmacist, clinical pharmacologist, a PhD in clinical pharmacology and precision medicine, and currently pursuing a masters in (clinical) epidemiology, his current work focuses on the personalised medicine of antihypertensive drugs.
Jonathan Knikman ensures the scientific coordination of the clinical trial (WP5) in the Hypermarker project, focused on personalised pharmacometabolomic optimisation of treatment for hypertension. Furthermore, he is also involved in the study of the influence of nutrition on the effectiveness of antihypertension drugs (WP3) and the prediction of response to antihypertensive drugs (WP4).
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis
Knikman, J. E., Wilting, T. A., Lopez-Yurda, M., Henricks, L. M., Lunenburg, C. A. T. C., de Man, F. M., Meulendijks, D., Nieboer, P., Droogendijk, H. J., Creemers, G.-J., Mandigers, C. M. P. W., Imholz, A. L. T., Mathijssen, R. H. J., Portielje, J. E. A., Valkenburg-van Iersel, L., Vulink, A., van der Poel, M. H. W., Baars, A., Swen, J. J. & Gelderblom, H. & 4 others, , 10 Dec 2023, In: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 41, 35, p. 5411-5421 11 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD
Knikman, J. E., Zhai, Q., Lunenburg, C. A. T. C., Henricks, L. M., Böhringer, S., van der Lee, M., de Man, F. M., Offer, S. M., Shrestha, S., Creemers, G. J., Baars, A., Dezentjé, V. O., Imholz, A. L. T., Jeurissen, F. J. F., Portielje, J. E. A., Jansen, R. L. H., Hamberg, P., Droogendijk, H. J., Koopman, M. & Nieboer, P. & 9 others, , 15 Aug 2024, In: Genome Medicine. 16, 1, 11 p., 101.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile -
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study
Knikman, J. E., de With, M., Heersche, N., Lopez-Yurda, M., Baars, A., Creemers, G.-J., Droogendijk, H. J., Fiets, E., Imholz, A. L. T., Iersel, L.V.-V., Mandigers, C. M. P. W., van de Vendel, A. J., Jeurissen, F. J. F., Nieboer, P., Deenen, M. J., van de Poel, M. H. W., Wymenga, M. N. M., van Schaik, R. H. N., van den Bosch, B. J. C. & Hoop, E.O.-D. & 8 others, , 25 Jun 2025, In: European Journal of Cancer. 224, 115483.Research output: Contribution to journal › Article › Academic › peer-review
-
Response to Letter Re: Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels
Heersche, N., Mathijssen, R. H. J., Cats, A., Guchelaar, H. J. & Knikman, J. E., 17 Nov 2025, In: European Journal of Cancer. 230, 115806.Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
-
Severe fluoropyrimidine toxicity in older adults with cancer with DPYD wild type
Brokaar, E., Knikman, J., Visser, L., van den Bos, F., Henricks, L., Lunenburg, C., de Man, F., Gelderblom, H., Schellens, J., Mathijssen, R., Guchelaar, H.-J., Portielje, J., Cats, A., Postmus, W. & de Glas, N., Apr 2025, In: Fundamental and Clinical Pharmacology. 39, 2, e70000.Research output: Contribution to journal › Article › Academic › peer-review
Open Access
Prizes
-
Joint EPHAR-EACPT Young Investigator Award in Translational Pharmacology
Knikman, J. E. (Recipient), 2024
Prize: Prize (including medals and awards)
-
KNMP-fondsen - onderzoek voor de apotheker in de praktijk
Knikman, J. E. (Recipient), 2024
Prize: Prize (including medals and awards)